LEXICON PHARMACEUTICALS, INC. (LXRX) Form S-3 — Aug 6, 2026
Lexicon Pharmaceuticals filed an S-3 shelf registration on August 6, 2026 to register 1,257,856 shares of common stock for resale by selling stockholders affiliated with Hercules Capital, the lenders under the company's May 4, 2026 Loan and Security Agreement. Lexicon will receive no proceeds; the shares are issuable upon exercise of warrants issued to the lenders in connection with that loan. The warrants carry an exercise price of $1.59 per share, are exercisable immediately, and expire five years from issuance. Based on the $2.42 fee-calculation price, the registered shares represent a maximum aggregate offering price of $3,044,011.52, and LXRX closed at $2.45 on August 5, 2026.
Key figures
- Shares Offered
- 1257856
- Shares Outstanding
- 444955934
- Warrant term
- exercisable immediately, expire five years from issuance (dated May 4, 2026)
- Treasury shares
- 1933747
- Dilution percent
- 0.28%
- Hercules warrant shares
- ["Hercules Capital, Inc.: 985,849","Hercules SBIC V, L.P.: 12,578","Hercules Private Credit Fund 1 L.P.: 117,923","Hercules Growth Lending Fund IV LP: 70,753","Hercules Evergreen Fund LP: 70,753"]
- Invus ownership percent
- 50.5%
- Authorized common shares
- 900000000
- Sec registration fee usd
- 420.38
- Stock close 2026 08 05 usd
- 2.45
- Warrant exercise price usd
- 1.59
- Fee calc price 2026 08 04 usd
- 2.42
Price after filing
Close on the filing date to close N calendar days later (from $2.49). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.